Conditions We Research

CONDITIONS WE RESEARCH

As a dynamic independently held clinical research site company, The ERG Network offers a deep bench of specialized expertise in more than 50 specific indications, with unparalleled capabilities in CNS studies.

Biomarkers have become a critical tool in speeding the success of clinical research trials, enabling researchers to precisely pinpoint target patient populations, inclusion and exclusion criteria, and optimal trial endpoints. ERG’s extensive experience testing biomarkers in diverse therapeutic areas helps streamline this process, accelerating the path to approval.

Demonstrated Expertise in Key Indications

  • Autism
  • Mild Cognitive Impairment

Learn more on ERGClinical.com +

Phase I studies help researchers determine how a drug works, by understanding its clinical pharmacology. Having conducted over 2000 Phase I studies, ERG is known throughout the industry for excelling in these trials. Most Phase I studies are conducted in normal healthy volunteers (NHV); NHVs are also used as a cohort of a Phase I study in metabolic, neurologic, psychiatric, endocrine, and cardiac disorders. We have access to a wide range of healthy subject profiles, and, whatever your compound, we stand ready to help you explore its clinical pharmacology.

Learn more on ERGClinical.com +

As scientists continue unlocking the human genome, they discover new methods of diagnosing and treating neurological disease—and ERG is at the forefront of translating this basic research into clinical solutions by advancing neurological clinical research studies.

Demonstrated Expertise in Key Indications

  • Autism
  • Cognitive Impairment
  • Dementia

Learn more on ERGClinical.com +